Released Aug 8, 2023, after the close
10-Q filed Aug 8, 2023, 39 days after period end · 0000950170-23-039803
Q2 2023 · 10-Q
Revenue$933.00K$933.00K −95.0% vs Q2 2022−98.4% vs Q1 2023
Net Income-$52.76M-$52.76M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.54-$0.54 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$62,565,000N/M
Operating Cash Flowderived-$28,493,000N/M
Free Cash Flowderived-$30,692,000N/M
Margins · derived
Operating margin-6705.8%−6257.7 pt vs Q2 2022
Net margin-5654.3%−5244.0 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $933.00K | $18.55M | $13.41M | $5.47M |
| Net Income | -$52.76M | -$76.11M | -$55.13M | -$28.07M |
| EPS Diluted | -$0.54 | -$0.79 | -$0.58 | -$0.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR